CCL20/MIP-3 alpha Antibody AF360 from R&D Systems, a Bio-Techne Brand

Product Specs
ItemCCL20/MIP-3 alpha Antibody
CompanyR&D Systems, a Bio-Techne Brand
Price $499.00Supplier Page View Company Product Page
Catalog NumberAF360
NCBI Gene AliasesST38, Exodus, MIP-3a, SCYA20, MIP-3-alpha, LARC, MIP3A, CKb4
ApplicationsBioassay,ELISA Development,Immunohistochemistry,Immunohistochemistry-Paraffin,Immunohistochemistry-Frozen,Neutralization,Immunocytochemistry
Quantity100 ug (also 25 ug)
Conjugate/TagUnconjugated
FormatLyophilized from a 0.2 µm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS
ReactivityHuman,Mouse
IsotypeIgG
HostGoat
TargetCCL20/MIP-3 alpha
NCBI Full Gene NameC-C motif chemokine ligand 20
ClonalityPolyclonal
ImmunogenE. coli-derived recombinant human CCL20/MIP-3 alpha, Ala27-Met96 (Asn95Asp), Accession # P78556
ConcentrationLYOPH
PurityAntigen Affinity-purified
Antibody TypePrimary Antibodies
StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution

Specifications/Features

Available conjugates: Available conjugates: Unconjugated

Specificity: Detects human CCL20/MIP-3 alpha in direct ELISAs.

Sizes Available: 100 ug (also 25 ug)

Add to Compare List

Questions and Answers

Can this antibody be used to study CCL20 expression in human tissues?

Yes, the CCL20/MIP-3 alpha antibody has been utilized in various studies to assess CCL20 expression in human tissues. For instance, it was employed in immunohistochemistry to investigate CCL20 levels in Hodgkin's lymphoma cells, demonstrating its effectiveness in detecting CCL20 in tumor microenvironments ().

Is this antibody effective for use in flow cytometry applications?

The CCL20/MIP-3 alpha antibody has been shown to work in flow cytometry applications, as indicated by its use in studies examining the migration of regulatory T cells in response to CCL20 levels in various contexts, including cancer and inflammation (, ).

How has this antibody been applied in research related to inflammatory diseases?

The CCL20/MIP-3 alpha antibody has been used to explore the role of CCL20 in inflammatory diseases, such as in the context of Helicobacter pylori infection, where it was shown that CCL20 expression is induced in gastric epithelial cells, contributing to gastric inflammation ().

Are there any studies that highlight the role of CCL20 in cancer research using this antibody?

Yes, the CCL20/MIP-3 alpha antibody has been referenced in studies investigating its role in cancer, particularly in lung adenocarcinoma, where CCL20 was found to promote tumor cell proliferation and migration through interactions with its receptor CCR6 ().

R&D Systems, a Bio-Techne Brand

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

Company Profile

Website: http://www.rndsystems.com

(1) Comparative analysis of senolytic drugs reveals mitochondrial determinants of efficacy and resistanceNature AgingJanuary 29, 2026Masahiro Wakita, Koyu Ito, Kaho Fujii, Dai Sakamoto, Takumi Mikawa, Sho Sugawara, Xiangyu Zhou, Jeong Hoon Park, Hideka Miyagawa, Daisuke Motooka, et al.1:50 dilution, sc-365870, Santa Cruz; CXCL5, 1:50 dilution, AF254, R&D Systems; CCL20, 1:50 dilution, AF360, R&D Systems; MMP3, 1:50 dilution, 66338-1-lg, Proteintech) overnight at 4 °C. The secondary antibody

(2) MAIT cell enrichment in Lynch syndrome is associated with immune surveillance and colorectal cancer riskResearch SquareSeptember 19, 2025Hairu Cadwell, Michaela Dungan, Michaela Beyries, Keely Beyries, Robert Kilpatrick, Robert Kilpatrick, Sangmi Chen, Marissa Berkowitz, Marissa Berkowitz, Sergei B Koralov, et al.temperature. Primary antibodies were incubated overnight at 4°C, targeting CCL20 (1:200, R&D Systems, Cat#AF360) and OLFM4 (1:150, Cell Signaling Technology, Cat# 14369T). After PBS washes, slides were incubated

(3) MAIT cell enrichment in Lynch syndrome is associated with immune surveillance and colorectal cancer riskbioRxivAugust 30, 2025Hairu Yang, Michaela Dungan, Keely Beyries, Xin Wang, Robert Kilpatrick, Baron Chen, Sangmi Oh, Marissa Berkowitz, David Smith, Sergei B Koralov, et al.temperature. Primary antibodies were incubated overnight at 4°C, targeting CCL20 (1:200, R&D Systems, Cat#AF360) and OLFM4 (1:150, Cell Signaling Technology, Cat# 14369T). After PBS washes, slides were incubated

(4) Migration arrest and transendothelial trafficking of human pathogenic-like Th17 cells are mediated by differentially positioned chemokinesNature communicationsFebruary 26, 2025Parween F, Singh SP, Kathuria N, Zhang HH, Ashida S, Otaizo-Carrasquero FA, Shamsaddini A, Gardina PJ, Ganesan S, Kabat J, et al.MAB679) CCL5 (5 μg, Cat# MAB278), CCL7 (5 μg, Cat# MAB282), CCL8 (5 μg, Cat# MAB281), CCL20 (5 μg, Cat# AF360), CXCL9 (5 μg, Cat# MAB392) from R&D Systems or with mouse IgG1 isotype control (5 μg, Cat# MAB002)

(5) An E. coli display method for characterization of peptide-sensor kinase interactionsNature chemical biologyApril 1, 2023Brink KR, Hunt MG, Mu AM, Groszman K, Hoang KV, Lorch KP, Pogostin BH, Gunn JS, Tabor JJ.

(6) Chemokine positioning determines mutually exclusive roles for their receptors in extravasation of pathogenic human T cellsbioRxiv : the preprint server for biologyFebruary 13, 2023Parween F, Singh SP, Zhang HH, Kathuria N, Otaizo-Carrasquero FA, Shamsaddini A, Gardina PJ, Ganesan S, Kabat J, Lorenzi HA, et al.chemokines CCL2 (5 μg, MAB679) CCL5 (5 μg, MAB278), CCL7 (5 μg, MAB282), CCL8 (5 μg, MAB281), CCL20 (5μg, AF360), CXCL9 (5 μg, MAB392), mouse IgG1 isotype control (5 μg, MAB002) and mouse IgG2B isotype control (MAB004)

(7) Tumor-associated neutrophils activated by tumor-derived CCL20 (C-C motif chemokine ligand 20) promote T cell immunosuppression via programmed death-ligand 1 (PD-L1) in breast cancerBioengineeredDecember 1, 2021Kwantwi LB, Wang S, Zhang W, Peng W, Cai Z, Sheng Y, Xiao H, Wang X, Wu Q.

(8) Gene expression profiling of primary human type I alveolar epithelial cells exposed to Bacillus anthracis spores reveals induction of neutrophil and monocyte chemokinesMicrobial pathogenesisAugust 1, 2018Booth JL, Duggan ES, Patel VI, Wu W, Burian DM, Hutchings DC, White VL, Coggeshall KM, Dozmorov MG, Metcalf JP.

(9) Role of CCL20/CCR6 and the ERK signaling pathway in lung adenocarcinomaOncology lettersDecember 1, 2017Zhang XP, Hu ZJ, Meng AH, Duan GC, Zhao QT, Yang J.the sections were incubated with goat anti‑human CCL20 monoclonal antibody (dilution, 1:100; cat. no. AF360; R&D Systems, Inc., Minneapolis, MN, USA) and mouse anti‑human CCR6 monoclonal antibody (dilution, 1:200;

(10) An initial investigation into endothelial CC chemokine expression in the human rheumatoid synoviumCytokineSeptember 1, 2017Rump L, Mattey DL, Kehoe O, Middleton J.CCL17 (10 µg/ml; AF364), mouse monoclonal CCL19 (20 µg/ml; MAB361), goat polyclonal CCL20 (10 µg/ml; AF360), goat polyclonal CCL21(15 µg/ml; AF366), goat polyclonal CCL24 (15 µg/ml; AF343), goat polyclonal CCL26

(11) Fusobacterium Nucleatum Subspecies Animalis Influences Proinflammatory Cytokine Expression and Monocyte Activation in Human Colorectal TumorsCancer prevention research (Philadelphia, Pa.)July 1, 2017Ye X, Wang R, Bhattacharya R, Boulbes DR, Fan F, Xia L, Adoni H, Ajami NJ, Wong MC, Smith DP, et al.

(12) Transforming Growth Factor-β and Interleukin-1β Signaling Pathways Converge on the Chemokine CCL20 PromoterThe Journal of biological chemistryJune 5, 2015Brand OJ, Somanath S, Moermans C, Yanagisawa H, Hashimoto M, Cambier S, Markovics J, Bondesson AJ, Hill A, Jablons D, et al.

(13) Preferential recruitment of Th17 cells to cervical cancer via CCR6-CCL20 pathwayPloS oneJanuary 1, 2015Yu Q, Lou XM, He Y.

(14) Microarray analysis of gene expression by microdissected epidermis and dermis in mycosis fungoides and adult T-cell leukemia/lymphomaInternational journal of oncologySeptember 1, 2014Hashikawa K, Yasumoto S, Nakashima K, Arakawa F, Kiyasu J, Kimura Y, Saruta H, Nakama T, Yasuda K, Tashiro K, et al.

(15) IL-22 negatively regulates Helicobacter pylori-induced CCL20 expression in gastric epithelial cellsPloS oneJanuary 1, 2014Chen JP, Wu MS, Kuo SH, Liao F.2.5% normal blocking serum for 30 min followed by the incubation with a primary antibody to CCL20 (AF360; R&D Systems, Minneapolis, MN) or IL-22 (ab18499, Abcam, Cambridge, MA) for overnight. Protein expression

(16) CCR6, the sole receptor for the chemokine CCL20, promotes spontaneous intestinal tumorigenesisPloS oneJanuary 1, 2014Nandi B, Pai C, Huang Q, Prabhala RH, Munshi NC, Gold JS.

(17) miR-21 and its target gene CCL20 are both highly overexpressed in the microenvironment of colorectal tumors: significance of their regulationOncology reportsSeptember 1, 2013Vicinus B, Rubie C, Stegmaier N, Frick VO, Kölsch K, Kauffels A, Ghadjar P, Wagner M, Glanemann M.USA). Overnight incubation of slides with primary goat polyclonal anti-human CCL20 antibody (15 µg/ml, AF360; R&D Systems) was followed by incubation with secondary biotinylated rabbit anti-goat IgG antibody and

(18) EBV infection is common in gingival epithelial cells of the periodontium and worsens during chronic periodontitisPloS oneJanuary 1, 2013Vincent-Bugnas S, Vitale S, Mouline CC, Khaali W, Charbit Y, Mahler P, Prêcheur I, Hofman P, Maryanski JL, Doglio A.

(19) Regulation of the psoriatic chemokine CCL20 by E3 ligases Trim32 and Piasy in keratinocytesThe Journal of investigative dermatologyMay 1, 2010Liu Y, Lagowski JP, Gao S, Raymond JH, White CR, Kulesz-Martin MF.anti-Trim32 antibody generated in our laboratory (Albor et al., 2006) or goat anti-CCL20 antibody, clone AF360 (R&D Systems Inc., Minneapolis, MN) overnight at 4°C. The specificity of chicken anti-Trim32 antibody

(20) Lung myeloid dendritic cells coordinately induce TH1 and TH17 responses in human emphysemaScience translational medicineOctober 28, 2009Shan M, Cheng HF, Song LZ, Roberts L, Green L, Hacken-Bitar J, Huh J, Bakaeen F, Coxson HO, Storness-Bliss C, et al.

Be the First to Write a Review!